Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
Pasithea Therapeutics宣佈首批隊列已完成其評估Ras、Nf1和Raf突變癌症Pas-004的1期試驗的初始給藥
Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
Pasithea Therapeutics宣佈首批隊列已完成其評估Ras、Nf1和Raf突變癌症Pas-004的1期試驗的初始給藥
使用瀏覽器的分享功能,分享給你的好友吧